BRUSSELS (Reuters) - The European Union reached a deal with Pfizer and BioNTech for 300 million additional doses of their COVID-19 vaccine, the head of the European Commission said on Friday, in a ...
Pharmaceutical Technology on MSN
Pfizer and Novavax ink $530m vaccine delivery licensing deal
Pfizer will now employ Novavax’s adjuvant, Matrix-M, into its vaccines across two disease areas.
An FDA review states that the benefits of Pfizer’s COVID-19 vaccine in kids ages 5 to 11 outweigh the potential risks, The Washington Post reported. The FDA noted in its review, released Oct. 22, that ...
The imminent authorization of Pfizer's Covid-19 vaccine in the United States is a momentous occasion for science, the economy and humanity. The milestone is also a major moneymaker for the companies ...
A Food and Drug Administration advisory committee voted 16-1 that the benefits of Pfizer’s PFE COVID antiviral Paxlovid outweigh the risks in adults who are at high risk of severe disease. The FDA is ...
Pfizer shares tumbled again Monday, continuing the pharmaceutical giant’s struggles tied to declining demand for its Covid-19 products and essentially wiping out the entirety of the firm’s peak ...
As the pandemic eased earlier this year, officials in Poland became vocal critics of the financial obligations laid down by Pfizer’s large vaccine supply pact with the European Union. Now, months ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results